

PRESS RELEASE

JHL Announces Its Proposed Voluntary Delisting from Emerging Stock Market of Taipei Exchange

11DEC2017

JHL Biotech, Inc. (TPEX: 6540) ("JHL" or the "Company") announced that, on December 8, 2017, the Company's board of directors (the "Board") resolved to initiate the process to voluntarily delist (the "Voluntary Delisting") of the Company's ordinary shares ("Shares") from the Emerging Stock Market of the Taipei Exchange ("TPEX") by submitting an application to TPEX after the proposal is approved by the shareholders meeting.

The Board believes the Voluntary Delisting is in the best interests of the Company and its shareholders. It better positions JHL to pursue its planned expansion activities and actively explore various, broad fundraising strategies (including a potential listing on an overseas exchange). Currently, the Company has a Phase I trial in Europe for its JHL1101 (rituximab biosimilar) in rheumatoid arthritis patients. In 2018, in addition to the Phase III trial in Europe for JHL1101, the Company further plans for Phase 1 and Phase 3 trials in China for JHL1101, Phase 1 and Phase 3 trials in Europe for JHL1922 (dornase alfa biosimilar), Phase 1 trial in Europe for JHL1149 (bevacizumab biosimilar), and Phase I trial in Europe for JHL1188 (trastuzumab biosimilar).

The Company tentatively plans to convene a shareholders meeting on or about February 1, 2018 to seek shareholders' approval for the Voluntary Delisting and other related proposals. If approved, shareholders may (1) request for share repurchase by the Company after the delisting on TPEX in accordance with applicable rules, (2) continue to sell shares on the market up to the delisting date, or (3) do nothing and continue remain on the register of members. In the event JHL is listed in an overseas exchange in the future, the Company will assist all then remaining shareholders to open a brokerage account in the relevant jurisdiction.

JHL Chairman James Huang, commented, "During the past five years, JHL has invested approximately US\$100 million in Taiwan and currently has nearly 150 employees in our headquarters and Center of Excellence in Taiwan. The Company has always been dedicated to social responsibility and corporate governance, and is committed to continue to invest in and grow with Taiwan. We truly believe access to worldwide capital markets will help the Company accomplish more sooner, and for the benefit of our shareholders. We sincerely hope that our shareholders will not only vote to support the Voluntary Delisting, but also remain with us for the exciting steps and success ahead."

This press release is not intended to, and shall not, constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the Shares in any state or

other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Safe Harbor Statement

This press release contains forward-looking statements. Statements in this press release that are not historical facts, including but not limited to the statements regarding JHL's future plans and its ability to complete the proposed Voluntary Delisting and maximize shareholder value, represent only the current expectations, assumptions, estimates and projections of the Company and are forward-looking statements. These forward-looking statements involve various risks and uncertainties. Important risks and uncertainties that could cause the actual results to be materially different from expectations include but are not limited to, capital markets conditions. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

End

Media Contact:

Jill Liu, Amber Chen

Phone: +886 3-658-3899

jliu@jhlbiotech.com, achen@jhlbiotech.com

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical firm founded by a group of biopharmaceutical industry veterans. JHL's investors include premier financial firms and strategic partners such as Kleiner Perkins Caufield & Byers, Biomark Capital, Milestone Capital, Sanofi, and Sequoia Capital. JHL is developing proposed biosimilars to rituximab, dornase alfa, bevacizumab, and trastuzumab. JHL1101, JHL's proposed rituximab biosimilar, is undergoing clinical trials in the European Union. In addition to biosimilars, JHL also co-develops innovative new molecules and provides contract manufacturing services to select clients. For more information, please visit www.jhlbiotech.com.